chartexchange

Mile High Labs Files Type II Drug Master File with FDA for CBD Isolate

PR Newswire | Nov 19, 2026 2:34 PM EST

Mile High Labs continues to build its pharmaceutical-channel capabilities with a Type II DMF for CBD Isolate LOVELAND, Colo., Nov. 19, 2026 /PRNewswire/ -- Mile High Labs, a global leader in hemp-derived cannabinoid ingredients, today announced that it has filed a Type II Drug Master File...

Read original article